Physician profile
Danielle G Johnson
NPI 1447602057
$1,417.20
in general payments reported to CMS, 2019-2025
19 companies · $425 in 2025
The $425 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $82.08 · 2022: $347 · 2023: $363 · 2024: $200 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.61 | 2021-2025 | |
| Novo Nordisk INC | $157.07 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.53 | 2021-2025 | Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.12 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $94.34 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $80.60 | 2022-2023 | Trelegy Ellipta |
| Exact Sciences Corporation | $62.75 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $45.91 | 2023-2024 | Repatha, Otezla |
| Sumitomo Pharma America, INC. | $44.72 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $41.37 | 2025 | Auvelity, Sunosi |
| Novartis Pharmaceuticals Corporation | $39.36 | 2022-2023 | |
| Dexcom, INC. | $33.54 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $27.23 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $24.64 | 2022 | |
| Mylan Specialty L.P. | $23.59 | 2024 | Yupelri |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.73 | 2022 | |
| Merck Sharp & Dohme LLC | $19.84 | 2022 | |
| Sanofi-Aventis U.S. LLC | $12.51 | 2022 | |
| Phathom Pharmaceuticals, INC. | $10.74 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.